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Abstract: Traumatic spinal cord injury (SCI) causes dramatic disability and dysfunction in the motor,
sensory and autonomic systems. The severe inflammatory reaction that occurs after SCI is strongly
associated with further tissue damage. As such, immunomodulatory strategies have been developed,
aimed at reducing inflammation, but also at shaping the immune response in order to protect, repair
and promote regeneration of spared neural tissue. One of those promising strategies is the intraspinal
administration of the cytokine interleukin-4 (IL-4) that was shown to promote a phenotype on specific
immune cells associated with neuroprotection and repair. In this work, we evaluated if a systemic
delivery of IL-4 for a 7-days period was also capable of promoting neuroprotection after SCI by
analyzing different neural cells populations and motor recovery. IL-4 treatment promoted an elevation
of the anti-inflammatory cytokine IL-10 in the serum both at 24 h and 7 days after injury. Locally,
treatment with IL-4 led to a reduction on cells expressing markers associated with inflammation,
CD11b/c and iNOS. Importantly, IL-4 treatment increased the neuronal markers βIII-tubulin and
NeuN, and the oligodendrocyte marker O4, suggesting a neuroprotective effect. Moreover, 100% of
the animals treated with IL-4 were able to recover weight support against only 33% of saline treated
animals. Overall, these results show that systemic administration of IL-4 positively impacts different
aspects of spinal cord injury, creating a more favorable environment for recovery to take place.
Keywords: spinal cord injury; neuroprotection; immunomodulation; Interleukin-4;
neuroimmunology
1. Introduction
Spinal cord injury (SCI) is a devastating neurological disorder that affects thousands of individuals
each year. In the US alone it is estimated an annual incidence of 40 cases per million population and
approximately 12,500 new SCI cases each year [1]. Despite the intense and interdisciplinary research
being performed on SCI topic, an effective treatment for SCI is still lacking.
After the initial trauma a cascade of events, also known as “secondary events”, occur that
contribute to further tissue damage and neurological deficits. As such, the acute phase after injury
represents a particularly interesting time window for candidate therapies since spared neurons
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from the initial trauma can be protected from secondary events. Among these events is the
excessive inflammatory response that comprises the activation of resident microglia and infiltrating
leukocytes. These cells start to release several cytokines and reactive oxygen species allowing additional
extravasation of leukocytes and further inflammation and tissue damage [2,3]. Thus, it is not surprising
that for the last few decades many of the efforts were to design candidate therapies aiming at
terminating with different aspects of inflammation [4,5]. In fact, the only pharmacological approach for
use in clinical settings was the acute administration of methylprednisolone, a potent anti-inflammatory
drug [6], although its efficacy is controversial and current guidelines recommendations support its
discontinuation [7–9].
While it is clear that an excessive proinflammatory response is a detrimental component of SCI
pathophysiology, it is also evident that immune cells are pivotal players for neural tissue repair and
regeneration by coordinating local and systemic responses to injury [10–13]. Based on this premise,
part of the research focus on SCI shifted from developing therapies to abrogate the inflammatory
response to developing immunomodulatory strategies aiming at reducing excessive proinflammatory
responses and promoting pro-regenerative immune phenotypes [14–18].
Interleukin-4 (IL-4) has emerged as an interesting therapy strategy in the context of SCI, due
to its ability to promote M2-alternative activation of macrophages [18,19], a phenotype associated
with neuroprotection and repair [20]. Indeed, impaired IL-4 signaling, such as in the case of IL-4
KO mice [12] or in aged microglia [21] was associated with poor spontaneous functional recovery
after SCI. Conversely, the restoration of IL-4 signaling by adoptive transfer of CD4+ T cells was
demonstrated to promote neuroprotection, axon regrowth and functional recovery after SCI in
mice [12], highlighting the importance of this cytokine to SCI-recovery. In fact, a single intraspinal
administration of IL-4 48 h after SCI was shown to be sufficient to skew macrophages and microglia
into an M2 phenotype, and more importantly, was associated with improved functional recovery in
SCI-mice [18]. This interesting finding prompted the question of whether a systemic delivery of IL-4,
rather than intraspinal, could represent a neuroprotective therapy since this is a more convenient route
of administration in clinical settings.
Therefore, in this work we aimed at exploring the long-term impact (8 weeks after injury) of
an acute/sub-acute IL-4 treatment on different neural cell populations and on functional recovery
in a rat model of contusion SCI. Specifically, we aimed to investigate if IL-4 delivered systemically
(intraperitoneal rather than intraspinal) can be used as a neuroprotective therapy for SCI.
2. Results
2.1. IL-4 Treatment Increased Circulating Levels of the Anti-Inflammatory Cytokine IL-10 and Reduced
Inflammatory Markers at the Spinal Cord of Injured Rats
Blood samples were collected at 24 h and 7 days post-injury in order to confirm that
the intraperitoneal administration of IL-4 was successfully reaching systemic bloodstream.
Cytokine analysis was performed, revealing a significant increase in the levels of IL-4 in the serum
from IL-4-treated animals when compared to the saline group (Figure 1A,C). Moreover, IL-4 treatment
significantly promoted an elevation of the anti-inflammatory cytokine IL-10, both at 24 h and
7 days post-injury (Figure 1B,D). At 24 h post-injury, the IL-4 serum concentration in saline-treated
animals was below detection limit while in the animals treated with IL-4 the concentration was
3451.2 ± 1165.5 pg/mL. At 7 days post-injury, the serum concentration of IL-4 was 13-fold
higher in IL-4-treated rats than in saline-treated animals (IL-4: 55.0 ± 25.0 pg/mL; Saline: 4.2 ±
7.1 pg/mL). The anti-inflammatory cytokine IL-10 was detected at both time points for the two groups.
However, 24 h post-injury the serum of IL-4-treated animals presented a 3.5-fold increase in IL-10 levels
compared to saline-treated animals (IL-4: 24.5 ± 10.9 pg/mL; Saline: 7.1 ± 7.3 pg/mL). The higher
concentration of IL-10 in IL-4-treated rats was also detected 7 days post-injury, with a 2-fold increase
when comparing to saline-treated rats (IL-4: 51.1 ± 25.7 pg/mL; Saline: 26.5 ± 17.5 pg/mL).
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Figure 1. Interleukin-4 (IL-4) administered intraperitoneally reaches systemic circulation and 
promotes an elevation of the anti-inflammatory cytokine IL-10. The serum concentration of the 
cytokine IL-4 at 24 h (A) and 7 days (C) post-injury and IL-10 at 24 h (B) and 7 days (D) post-injury 
are significantly increased in the IL-4-treated rats. Values shown as mean ± SEM. * p < 0.05; ** p < 0.01; 
*** p < 0.001. 
Histological analysis was performed at the chronic phase (8 weeks post-injury) in order to assess 
the long-term impact of IL-4 treatment.  
Macrophages/microglia were quantified through the expression of CD11b/c in two different 
regions of the spinal cord: the cavitation area and in spared tissue (Figure 2C). 
 
Figure 2. IL-4 treatment reduces the area of macrophages/microglia in the injured spinal cord. 
Distribution of the CD11b/c+ area along the rostrocaudal axis of the spinal cord (A). Quantification of 
CD11b/c+ area in the whole spinal cord revealed a significant reduction of macrophages in IL-4-treated 
rats (B); A significant reduction of CD11b/c+ area was also observed in the rostral (E); epicenter (F) 
and caudal (G) regions of the injured spinal cord. Schematic and low-magnification photomicrograph 
indicating areas where the analyses were performed (dashed lines) (C); Representative images of 
positive staining for macrophages/microglia of saline (D) and IL-4 treated (H) group. Values shown 
as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001. Scale bar = 100 μm. 
Figure 1. Interl ukin-4 (IL-4) administered intraperiton ally r ches systemic circulation and pr motes
an elevation of the nti-inflamm tory cytokine IL-10. The s rum concentration of the cytokine IL-4 at
24 h (A) and 7 days (C) post-injury and IL-10 at 24 h (B) and 7 days (D) post-injury are significantly
increased in the IL-4-treated rats. Values shown as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.
Histological analysis was performed at the chronic phase (8 weeks post-injury) in order to assess
the long-term impact of IL-4 treatment.
Macrophages/microglia were quantified through the expression of CD11b/c in two different
regions of the spinal cord: the cavitation area and in spared tissue (Figure 2C).
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Figure 2. IL-4 treatment reduces the area of macrophages/microglia in the injured spinal cord.
Distribution of the CD11b/c+ area along the rostrocaudal axis of the spinal cord (A). Quantification of
CD11b/c+ area in the whole spinal cord reve led a significant reducti n of macrophages in IL-4-treate
rats (B); A significant reduction of CD11b/c+ area was also observed i the rostral (E); epicenter (F)
and caudal (G) regions of t e injured spinal cord. Schematic an low-magnification photomicr graph
indicating areas where the analyses were perform d (d shed lin s) (C); Representative images of
positive st ining for macrophages/microglia of saline (D) and IL-4 treated (H) group. Values shown as
mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001. Scale bar = 100 µm.
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Analysis of CD11b/c-positive cells revealed that IL-4 treatment significantly decreased the area
occupied by macrophages (Figure 2A,B) on the spinal cord. The analysis of specific regions of the
spinal cord demonstrated that the significant decrease of macrophages occurred both rostral (Figure 2E)
and caudally to the epicenter (Figure 2G), as well as around the epicenter area (Figure 2F).
Besides the evaluation of the macrophages/microglia numbers, it was also analyzed the number
of iNOS-positive cells, an enzyme associated with oxidative stress (Figure 3C). IL-4 treatment
significantly reduced the iNOS-positive cells along the spinal cord when compared with saline
treatment (Figure 3A,B). However, the analysis on specific regions of the spinal cord only revealed a
statistically significant decrease of iNOS-positive cells rostrally to the epicenter (Figure 3E). Around
(Figure 3F) and caudally (Figure 3G) to the epicenter it is possible to observe a clear trend for the
decrease of iNOS-positive cells in the IL-4-treated group, however, no statistically significant differences
were found.
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Interestingly, IL-4 treatment also led to morphological changes in macrophage/microglia cells. 
IL-4 treatment promoted a more ramified morphology in macrophage/microglia cells present at the 
lesion epicenter as shown by an increase on the number of intersecting ramification with concentric 
circles from a sholl plot (Figure 4). 
Figure 3. IL-4 treatment reduces the numb S-expressing cells in the injured spinal cord.
Distribution of iNOS+ cells l the rostrocaudal axis of the spinal cord (A); Quantification of
iNOS+ cells in the whole spinal cord revealed a significant reduction of iNOS-producing cells in
IL-4-treated rats (B); A significant reduction of iNOS-expressing cells was also observed in the rostral
(E) area of the spinal cord but not at the epicenter (F) and in the caudal (H) regions. Schematic and
low-magnification photomicrograph indicating areas where the analyses were performed (dashed
lines) (C); Representative images of positive staining for iNOS+ cells of saline (D) and IL-4 treated (H)
group. Values shown as mean ± SEM. * p < 0.05; ** p <0.01. Scale bar = 100 µm.
Interestingly, IL-4 treatment also led to morphological changes in macrophage/microglia cells.
IL-4 treatment promoted a more ramified morphology in macrophage/microglia cells present at the
lesion epicenter as shown by an increase on the number of intersecting ramification with concentric
circles from a sholl plot (Figure 4).
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macrophages/microglia. On the right, microglia immunofluorescence images were transformed into 
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Figure 4. IL-4 treatment promotes a more ramified morphology (less active) on macrophages/microglia.
On the right, microglia immunofluorescence images were transformed into binary and then analyzed
with a sholl plot. Then, it was quantified the number of intersections with each sholl plot concentric
circle. *** p < 0.001.
2.2. IL-4 Treatment In rea ed e Number of Moto Neurons and Oligodendrocytes, while no Impact Was
Observed on Astrocytes in the Spinal Cord of Injured Rats
We first assessed the europrotective effect of IL-4 o m tor neurons. For that we quantified
the number of motor neurons on the ventral horns using the neur nal marker NeuN and the
area of expression of βIII-tubulin, a cytoskeletal protein and a major constituent of a neuron’s
microtubules [22].
Overall, IL-4 treatment led to an increase in the number of motor neurons in the ventral horns
(Figure 5A,B). When the analysis was divided into rostral, epicenter and caudal region, it was observed
that this increase of motor neurons was confined to the epicenter region (Figure 5E–G).
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Figure 5. IL-4 treatment increases the number of motor neurons in the ventral horns. Distribution
of the NeuN+ cells along the rostrocaudal axis of the spinal cord (A); Quantification of NeuN+ cells
in the whole spinal cord revealed a significant increase of motor neurons in IL-4-treated rats (B);
A significant increase of motor neurons was also observed at the epicenter region of the spinal cord (F);
while in the rostral (E) and at the caudal (G) areas no differences could be observed. Schematic image
indicating areas where the analyses were performed (C); Representative i ages of positive staining
for motor neurons of saline (D) and IL-4 treated (H) group. Values shown as mean ± SEM. * p < 0.05.
Scale bar = 100 µm.
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The quantification of the area occupied by βIII-tubulin-positive cells revealed a significant increase
in the stained area in the caudal zone of the IL-4-treated rats’ spinal cords (Figure 6G). Although, the
same effect was not verified when the analysis included the whole spinal cord (Figure 6B) or was
performed on other specific regions of the spinal cord, such as the rostral (Figure 6E) or the epicenter
(Figure 6F) zone.
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The effect of IL-4 treatment on oligodendrocytes, the myelinating cells of the spinal cord 
neurons, was evaluated by quantifying O4, a marker for type I and II oligodendrocytes [23]. Overall, 
IL-4 treatment increased the number of oligodendrocytes (Figure 7A) on the injured spinal cord. Both 
the analysis to the whole spinal cord (Figures 7D) or to its specific rostral and caudal regions (Figure 
7E,F) revealed a significant increase in the number of oligodendrocytes from IL-4-treated rats. 
The effect of IL-4 on astrocytes was also evaluated using immunohistochemistry against the glial 
fibrillary acidic protein (GFAP). The positive stained area for GFAP was quantified along the rostral 
to caudal axis of the spinal cord (Figure 8A). The analysis demonstrated that IL-4 treatment did not 
alter GFAP-positive stained area in any region of the spinal cord (Figure 8).  
Figure 6. IL-4 treatment increases the area of stai i for βIII-tubuli in the caudal part of the injured
spinal cord. Distribution of βIII-tubulin positive area along the rostrocaudal axis of the spinal cord (A);
Quantification of βIII-tubulin+ area in the whole spinal cord did not reveal any differences between
saline or IL-4 treated rats (B) however a significant increase of βIII-tubulin area was observed in the
caudal (G) area of the spinal cord of IL-4-treated rats; In the epicenter (F) and in the rostral (E) area no
differences were observed. Schematic and low-magnification photomicrograph indicating areas where
the analyses were performed (dashed lines) (C); Representative images of positive staining of neuronal
cytoskeleton of saline (D) and IL-4 treated (H) group. Values shown as mean ± SEM. *** p < 0.001.
Scale bar = 100 µm.
The effect of IL-4 treatment on oligodendrocytes, the myelinating cells of the spinal cord neurons,
was evaluated by quantifying O4, a marker for type I and II oligodendrocytes [23]. Overall, IL-4
treatment increased the number of oligodendrocytes (Figure 7A) on the injured spinal cord. Both the
analysis to the whole spinal cord (Figure 7D) or to its specific rostral and caudal regions (Figure 7E,F)
revealed a significant increase in the number of oligodendrocytes from IL-4-treated rats.
The effect of IL-4 on astrocytes was also evalu ted u ing immunohistochemistry against the glial
fibrillary acidic rotein (GFAP). The positive stained area for GFAP was quantified along the rostral to
caudal axis of the spinal cord (Figure 8A). The analysis demonstrated that IL-4 treatment did not alter
GFAP-positive stained area in any region of the spinal cord (Figure 8).
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Figure 8. IL-4 treatment does not affect astrocyte numbers after SCI. Distribution of the percentage of 
GFAP+ area along the rostrocaudal axis of the spinal cord (A); The quantification of GFAP+ area either 
in the whole spinal cord (B) or in the specific regions (rostral (E); epicenter (F) and caudal (G)) did 
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Figure 7. IL-4 treatment increases the number of oligodendrocytes in the injured spinal cord.
Distribution of the O4+ cells along the rostrocaudal axis of the spinal cord (A); Quantification of
O4+ cells in the whole spinal cord revealed a significant increase of oligodendrocytes in IL-4-treated
rats (D); A significant increase of oligodendrocytes was also observed in the rostral (E) and caudal (F)
regions of the injur d spinal cord. Schematic and low-magnification photomicrograph indicating areas
where the analyses were performed (dashed lines) (B); Representative images of positive staining for
oligodendrocytes of saline (C) and IL-4 treated (G) group. Values shown as mean ± SEM. * p < 0.05;
** p < 0.01; *** p < 0.001. Scale bar = 100 µm.
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2.3. IL-4 Treatment: The Effect on Motor Recovery and Lesion Size
The Basso, Beattie and Bresnahan (BBB) score was applied in order to assess the locomotor
behavioral recovery from SCI and was applied every week until week 7. Both saline and IL-4
treated group show a spontaneous improvement on the BBB score over time stabilizing after 2 weeks
(Figure 9A). After 7 weeks (time of last BBB evaluation) the saline treatment-group had a BBB score of
8.5 ± 3.2 and the IL-4 treatment group a score of 9.6 ± 0.2 (Figure 9A). The mean between groups was
not statistically significant, however, it is important to point out that 100% of the animals treated with
IL-4 were able to recovery weight support against only 33% of saline treated animals.
The size of lesion tissue was quantified using hematoxylin–eosin staining. The analysis of the
percentage of lesion tissue revealed that IL-4 treatment did not alter the percentage of lesion (Figure 9B).
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The raised levels of this anti-inflammatory cytokine is particularly interesting since IL-10 has
the ability to suppress cellular immunity and inhibit the synthesis and release of pro-inflammatory
mediators [26,27] possibly counteracting the excessive inflammatory reaction seen after SCI. Indeed, the
direct administration of IL-10 in animal models of SCI was demonstrated to promote neuroprotection,
neuronal survival and functional improvements [28–30].
After confirming that IL-4 was in circulation during the acute/sub-acute phase after injury,
we focused on the long-term (8 weeks after SCI) effects of IL-4 treatment on cellular and functional
recovery. At first we assessed markers associated with inflammation and observed significant reduction
of CD11b/c-positive cells (Figure 2) that may reflect reduced numbers of infiltrating macrophages
and/or resident microglia and of iNOS-producing cells (Figure 3), an enzyme associated with oxidative
activity and mainly induced by M1-macrophages. Reducing iNOS-producing cells may be protective
for spinal cord injury as excessive iNOS expression in SCI is associated with oxidative damage and
neuronal death [31–35]. Interestingly, macrophage/microglia changed morphology in response to
IL-4 treatment from a more amoeboid state into a more ramified, a morphology associated with a less
activated phenotype [36].
An important correlate of the reduced inflammatory response observed after IL-4 treatment is
the increased numbers of motor neurons observed after treatment suggesting a neuroprotective effect
of IL-4. In fact, additionally to the total number of motor neurons, we also observe an increase in
βIII-tubulin stained area, possibly reflecting an enhanced structural preservation of motor neurons.
However we cannot exclude that IL-4 treatment promoted axonal regeneration. Previous studies
supported both an effect of IL-4 on protection and regeneration. For example, IL-4 was shown to
promote motor neuron survival through STAT6 signaling in a model of peripheral nerve injury [37],
while in dorsal root ganglion cells, IL-4 enhanced axonal regeneration through the stimulation of local
neurotrophin secretion [38]. Walsh and colleagues demonstrated that the IL-4 receptor is expressed
on spinal cord axons [12], so it is possible that the effects of IL-4 on axonal regeneration in peripheral
nerve are also transversal to spinal cord axons.
Additionally we observed that beyond neuronal cells, IL-4 treatment increased the number of
oligodendrocytes as shown by an increase in the numbers of O4-positive cells. Although also expressed
in mature oligodendrocytes, O4 starts to be expressed in progenitors cells [39]. Therefore, a possible
explanation for this increase in O4-positive cells induced by IL-4 treatment may be an increase in
the formation of new oligodendrocytes. In line with this, is the study by Butovsky and co-workers
showing that co-culturing neural precursors cells (NPCs) with microglia pre-exposed to IL-4 promoted
oligodendrogenesis [40]. However, it is also known that activated macrophages/microglia may induce
oligodendrocyte death and myelin damage through secreted factors [41], therefore, IL-4 treatment in
our study may have protected existing mature oligodendrocytes, a fact supported by the IL-4-induced
reduction in the numbers of macrophages/microglia observed in our study.
Our study demonstrated that IL-4 administration after a SCI, despite altering
macrophages/microglia, oligodendrocytes and neurons, did not influence astrocytes. It is
important to note that the role of astrocytes after a SCI is very complex and whether it has beneficial
or detrimental effects is yet to be clearly demonstrated. Despite several studies showing that the
astrocytic scar is a physical and chemical barrier against axonal regeneration [42,43] some other
studies have shown a beneficial and crucial role of astrocytes after a SCI. For instance, the elimination
of reactive astrocytes or, the prevention of their migration, and scar formation after injury resulted
in a failure of blood-brain barrier repair accompanied by massive inflammatory cell infiltration and
increased loss of neurons and oligodendrocytes leading to worse functional outcomes [44,45]. More
recently, Anderson and colleagues [46] demonstrated that preventing, attenuating or ablating the
astrocytic scar does not promote spontaneous axonal regeneration. On the contrary, they demonstrated
that the astrocytic glial scar aids axonal regeneration [46].
Curiously, although IL-4 treatment had a protective effect in both neuronal and oligodendrocyte
populations, this was not significantly reflected by the expected reduction of the size of the injured
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tissue. However, analysis of spared tissue does not take into account important factors, such as the
presence of non-functional fibrotic tissue. Indeed, in the images of NeuN staining (Figure 5) it is
possible to see that the saline group present intact tissue at the epicenter region, however, motor
neurons were unable to survive, most likely due to neurodegeneration. Moreover, these differences in
the functionality of the spared tissue are more likely correlated with the improvements observed in
some features of locomotion. Indeed, we here demonstrated that similarly to what was previously
demonstrated for a intraspinal IL-4 administration [18], a more clinically relevant administration of
IL-4 (intraperitoneal injections) was also able to achieve an important landmark of motor recovery
– the ability of rats to support their own weight. In fact, the BBB scores for the IL-4 group ranged
between 9 and 10 meaning that while all the rats recovered weight support when stationary, some of
the them were even able to perform occasional weight supported plantar stepping.
Although treatment with IL-4 led to significant neuroprotective effects, the recovery is still partial
and far from complete perhaps because IL-4 only targets only some of the many aspects of this
complex injury.
In this sense, IL-4 could be potentially used as part of a combinatory strategy either with other
immunomodulatory therapies targeting, for example, adaptive immune cells [17] as well as with other
regenerative strategies such as cell therapy [47], biomaterials [48] or other molecular therapies focused
in neuroprotection or neuroregeneration.
4. Materials and Methods
4.1. Spinal Cord Injury Model and Treatment
Twelve Wistar Han female rats (14 weeks old, weighing 210–260 g) were used in this study.
Animals were kept under standard laboratory conditions (12 h light: 12 h dark cycles, 22 ◦C, relative
humidity of 55%, ad libitum access to standard food and water), and housed in pairs. Animal handling
was carried out 3 days prior to surgery. Animals were subjected to a severe contusive SCI as previously
described [49,50]. General anaesthesia was induced by an intraperitoneal injection (i.p.) of ketamine
(100 mg/mL, Imalgene/Merial, Duluth, GA, USA) and medetomidine hydrochloride (1 mg/mL,
Dormitor/Pfizer, New York, NY, USA) mixture, at a volume ratio of 1.5:1. Once anesthetized,
animals received subcutaneous injections of the analgesic butorphanol (10 mg/mL, Butomidor/Richter
Pharma AG, Wels, Austria), and the antibiotic enrofloxacin (5 mg/mL, Baytril/Bayer, Leverkusen,
Germany). The fur was shaved from the surgical site and the skin disinfected with ethanol 70% and
chlorohexidine. Surgical procedures were performed under sterile conditions. The animals were placed
in a prone position and a dorsal midline incision was made at the level of thoracic spine (T5–T12). The
paravertebral muscles were retracted and the spinous processes and laminar arc of T8 was removed,
and the spinal cord exposed. The dura was left intact. A weight drop trauma model was used, that
consisted in dropping a 10 g weight rod from a 20 cm height onto the exposed spinal cord [49]. The
rod was guided through a stabilized tube that was positioned perpendicularly to the centre of the
spinal cord. After the trauma, the muscles were sutured with Vicryl suture (Johnson and Johnson, New
Brunswick, NJ, USA) and the incision closed with surgical staples (Fine Science Tools, Heidelberg,
Germany). Anesthesia was reversed using atipamezole (5 mg/mL, Antisedan/Pfizer, New York, NY,
USA). One-hour post-injury, animals were randomly divided into two experimental groups: IL-4
treatment (rat recombinant IL-4 (Kemprotec, Carnforth, UK) (0.35 µg/kg) and controls that received
only vehicle (saline). The dosage selected was based on other studies using intraperitoneal injection of
cytokines after a SCI [30,51]. Treatment and saline was administered i.p. every 12 h for 7 days to target
the peak of macrophage infiltration [52].
Post-operative care for all rats included butorphanol (Richter Pharma AG, Wels, Austria)
administration twice a day, for a five-day period as well as vitamins (Duphalyte, Pfizer, New York, NY,
USA), saline, and enrofloxacin (Bayer, Leverkusen, Germany), twice a day for a 7-day period. Manual
expression of bladders was performed twice a day until animals recovered spontaneous voiding. Body
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weight was monitored weekly as a parameter of general health of the animals. If a weight loss over
10% of body weight was detected, a high-calorie oral supplement (Nutri-Cal®) was administered daily.
4.2. Behavioral Assessment
The BBB locomotor rating scale [53] was used to evaluate functional recovery. Researchers
performed all behavioral tests blindly to the treatment groups. The BBB test was performed three
days post-injury and thereafter weekly for a 7-week period. A BBB score of 0 indicates no hindlimb
movement. A BBB score of 1 through 8 indicates joint movement, but no weight support. A BBB score
of 9 through 20 indicates an ability to support weight and use the limb for locomotion but with some
degree of abnormality. A BBB score of 21 corresponds to the locomotion of a normal rat.
4.3. Serum Cytokine Analysis
After 24 h and 7-days post-injury, blood was collected from the tail and allowed to clot for
30 min before centrifugation (10 min at 10,000×g). Then, serum was collected and frozen at −80 ◦C.
An enzyme-linked immunosorbent assay for IL-4 and IL-10 detection (Millipore) was used and the
assay was performed as instructed by the supplier. Samples were analyzed in a MAGPIX Luminex’s
xMAP® instrument (Luminex, Austin, TX, USA).
4.4. Histological Assessment
Eight-weeks post-injury, animals were deeply anesthetized by an i.p. injection of sodium
pentobarbital (200 mg/mL, Eutasil/Ceva Sante Animale, Libourne, France) and transcardially
perfused with 100 mL of cold 0.9% saline followed by 300 ml of 4% paraformaldehyde (PFA) in
1× phosphate-buffered saline (PBS). A rough dissection of the vertebral column and spinal cord was
performed and tissues were fixed in a solution of 4% PFA for 24 h (4 ◦C). The spinal cord was then
dissected from the vertebral column and immersed in a cryoprotectant solution—30% sucrose, for 48 h
at 4 ◦C. Afterwards, 2 cm length of spinal cord tissues, centered on the lesion, were submerged in
optimal cutting temperature (OCT) embedding medium, frozen on dry ice, and stored at −20 ◦C.
To minimize bias, each spinal cord was coded to keep the experimenter blind to the treatment.
Cross-sections of 20 µm thickness were performed using a cryostat (Leica CM1900, LeicaBiosystems,
Nussloch, Germany) and thaw-mounted onto charged microscope slides (Superfrost Plus, Thermo
Scientific, Waltham, MA, USA). All histological procedures and evaluation were performed blindly to
the treatment groups.
4.5. Hematoxylin–Eosin Staining
Tissue slides were stained for hematoxylin–eosin staining and then photographed with a
stereology microscope (Zeiss Axioplan 2 Imaging, Jena, Germany) using a 2.5× objective. Evaluation
of damaged tissue was performed on transverse sections (150 µm apart) along the rostrocaudal axis.
The areas were manually traced and quantified using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
4.6. Immunohistochemistry Protocol
For immunofluorescence staining, slices were washed with PBS, permeabilized with 0.2% Triton
X-100 for 10 m and blocked with 5% fetal calf serum in 0.2% Triton X-100 for 30 m. Afterwards,
the following primary antibodies were incubated overnight at room temperature (RT): mouse
anti-CD11b/c for microglia and macrophages (1:100; Pharmingen, San Diego, CA, USA); rabbit
inducible nitric oxide synthase (iNOS) (1:100; Millipore, Darmstadt, Germany), mouse anti-βIII-tubulin
for neuronal cytoskeleton (1:1000; Promega, San Luis Obispo, CA, USA), mouse anti-O4 for
oligodendrocytes (1:200, Millipore, Darmstadt, Germany), rabbit anti-GFAP for astrocytes (1:200;
Dako Denmark, Glostrup, Danmark) and mouse anti-NeuN for neurons (1:200, Millipore, Darmstadt,
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German). The following day primary antibodies were then probed (2 h incubation) with the appropriate
Alexa 594- or Alexa 488-conjugated secondary antibodies (1:1000; Invitrogen, Paisley UK). Sections
were counterstained with DAPI for 30 m (1:1000; Sigma, Saint Louis, CA, USA) and mounted with
Immu-Mount® (Thermo Scientific, Waltham, MA, USA). Between steps, 5 washes with PBS (1×) were
performed. For all immunofluorescence procedures, the appropriate negative controls were obtained
by omission of the relevant primary antibody. Images were acquired using confocal point-scanning
microscope, Olympus FV1000. All images were analyzed using ImageJ and FIJI software.
4.7. Immunofluorescence Analysis
Spinal cord immunostaining was analyzed by collecting photomicrographs every 150 µm both
rostrally and caudally from the epicenter. The epicenter region was considered the area ranging from
−300 µm and 300 µm surrounding the lesion epicenter. The most rostral area analyzed extended
from −1200 µm to −300 µm from the lesion epicenter and the most caudal area analyzed extended
from 300 µm to 1200 µm from the lesion epicenter. A section’s exclusion criteria for analysis were:
shattered, cracked or folded sections or sections washed off during immunostaining procedure.
After obtaining micrographs through confocal microscopy, the photos were opened with the Image
J software. For cell counting, the multi-point tool was used. For positive area measurements, first the
scale was determined and then the images were converted to 8 bits and were processed in the menu
“make binary”. Finally, using the menu “analyze particles”, the software automatically calculated the
areas occupied by each marker, using the dark background as contrast.
The immunofluorescence quantification in each photomicrograph was assessed by positive-cell
counting (for the iNOS, NeuN and O4 markers) or positive staining area (for the CD11b/c, βIII-tubulin
and GFAP area). Specifically, the analysis for the CD11b/c marker was performed in two random
fields of each photomicrograph (Figure 2C). Since the staining for this marker in the epicenter region
was heterogeneous due to the presence of a cavitation, the strategy was to select one field within the
cavitation and other field outside the cavitation. Quantification of iNOS-positive cells was assessed in
niches of positive cells in each section (Figure 3C). NeuN-positive cells were counted in the ventral
horns of the gray matter (Figure 4C).βIII-tubulin positive area was measured on the ventral horns of the
gray matter (Figure 5C). O4-positive cells were counted in two specific motor tracts, the vestibulospinal
and the reticulospinal tracts Figure 6B) (the corticospinal tract was analyzed but no positive staining
was found). Identification of tracts was according to the spinal cord atlas [54]. Data plotted in the
graphs represent mean numbers (or area) per section. Data plotted in the graphs represent mean
numbers (or area) per section. Finally, the GFAP-positive area was measured on the entire spinal cord
slice using lower magnification (Figure 7C). Due to cavitation the GFAP-positive area is presented in
percentage for the total spinal cord tissue.
4.8. Macrophages/Microglia Sholl Analysis
Z-stack confocal images of spinal cord section stained for CD11b/c were acquired using a confocal
microscope and loaded into FIJI software. Images were thresholded to binary to include complete
macrophage/microglia processes. A single macrophage/microglia cell was isolated by erasing
surrounding processes from other cells, using the eraser tool. The longest process was drawn using the
line segment tool. Using the sholl analysis function, the first shell was defined at 10 µm from the soma
center (to exclude soma from the analysis) and each subsequent step at 5 µm. Analysis was performed
using spinal cord sections representative of the lesion epicenter. Two to three macrophage/microglia
cells per section were randomly selected for analysis. Exclusion criteria for macrophage/microglia cell
selection for analysis were: incomplete processes or macrophage/microglia with processes near to
the margins. Number of intersections with each concentric shell was automatically calculated by the
software considering a linear profile.
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4.9. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.00 software. The normality of the
data was evaluated by the Kolmogorov-Smirnov normality tests. When the equal variances criterion
was not met, Welch correction was applied.
Data from macrophage/microglia sholl analysis and BBB test was assessed by a two-way ANOVA
test. Differences between groups were compared with the post hoc Bonferroni test.
Immunofluorescence and cytokine concentration data were analyzed using the Student’s t-test
or Mann-Whitney according normality results. Statistical significance was defined for p < 0.05 (95%
confidence level). Data are shown as mean +/− standard error (SEM).
5. Conclusions
Our results show that IL-4 treatment for 7-days led to a reduced inflammatory profile and
enhanced neuronal and oligodendrocytes populations while having no significant impact in astrocytes.
Moreover, IL-4 treatment improved some features of the motor behaviour of SCI animals. The
successful impact of IL-4 treatment in histological and functional aspects of SCI highlights the potential
of this therapy on integrating other therapeutic approaches. However, more pre-clinical studies are
needed to determine if IL-4 can enter in clinical trials in the future to be used in established clinical
protocols directed towards SCI.
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